Vanessa R Guimarães

Dr. Vanessa R Guimarães

Faculdade de Medicina da Universidade de São Paulo - FMUSP, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
RKRebeca Kawahara
Rebeca Kawahara
FOFabio Ortega
Fabio Ortega
LRLivia Rosa-Fernandes
Livia Rosa-Fernandes
VGVanessa R Guimarães
Vanessa R Guimarães
DQDaniel Quina
Daniel Quina
Giuseppe PalmisanoGiuseppe Palmisano
Giuseppe Palmisano
Distinct urinary glycoprotein signatures in prostate cancer patients Distinct urinary glycoprotein signatures in prostate cancer patients

6 November 2018 in Tumor Biology
Verified
Journal Article
Open access
PDF file
Ruan PimentaRuan Pimenta
Ruan Pimenta
NVNayara I Viana
Nayara I Viana
GAGabriela Q Amaral
Gabriela Q Amaral
RPRubens Park
Rubens Park
DMDenis R Morais
Denis R Morais
SRSabrina T Reis
Sabrina T Reis
The acquisition of a castration-resistant prostate cancer phenotype by prostate cancer cells is the alteration that has the worst prognosis for patients. The aim of this study was to evaluate the role of the microRNAs-23b/-27b as well as the possible CCNG1 target gene in tissue samples from patients with localized prostate cancer that progressed to castration-resistant prostate cancer and in a castration-resistant prostate cancer cell line (PC-3). The microRNAs and target gene expression levels of the surgical specimens were analyzed by quantitative real-time polymerase chain reaction. The prostate cancer cell line, PC-3, was transfected with pre-miR-23b, pre-miR-27b, and their respective controls using Lipofectamine RNAiMAX and exposed or not to flutamide. After transfections, expression levels of both the microRNAs and the gene, CCNG1, were analyzed by quantitative real-time polymerase chain reaction. The apoptosis and cell cycle assays were performed on the mini MUSE cytometer. MicroRNAs-23b/-27b were underexpressed in surgical specimens of prostate cancer; however, their target gene, CCNG1, was overexpressed in 69% of the cases. After transfection with the microRNAs-23b/-27b and flutamide, we observed a reduction in gene expression compared with cells that were treated only with microRNAs or only with flutamide. In the apoptosis assay, we demonstrated cell sensitization following transfection with microRNAs-23b/-27b and potentiation when co-administered with flutamide. The number of cells in apoptosis was almost three times higher with the simultaneous treatments (miR + flutamide) compared with the control (p < 0.05). In the cell cycle assay, only flutamide treatment showed better results; a higher number of cells were found in the G0-G1 phase, and a lower percentage of cells completed the final phase of the cycle (p < 0.05). We conclude that microRNAs-23b/-27b are downexpressed in prostate cancer, and their target gene, CCNG1, is overexpressed. We postulated that microRNAs-23b/-27b sensitize the PC-3 cell line and that after the addition of flutamide in the apoptosis assay, we would observe synergism in the treatments between miR and flutamide. In the cell cycle assay, the use of flutamide was sufficient to decrease the number of cells in mitosis. Therefore, we postulate that microRNAs, along with other drugs, may become very useful therapeutic tools in the treatment of castration-resistant prostate cancer.

Verified
Journal Article
Open access
PDF file
JCJuliana Camargo
Juliana Camargo
NVNayara Viana
Nayara Viana
Ruan PimentaRuan Pimenta
Ruan Pimenta
VGVanessa R Guimarães
Vanessa R Guimarães
GSGabriel Arantes dos Santos
Gabriel Arantes dos Santos
SRSabrina T. Reis
Sabrina T. Reis
Prostate cancer (PCa) has a high prevalence and represents an important health problem, with an increased risk of metastasis. With the advance of CRISPR-Cas9 genome editing, new possibilities have been created for investigating PCa. The technique is effective in knockout oncogenes, reducing tumor resistance. MMP9 and miR-21 target genes are associated with PCa progression; therefore, we evaluated the MMP-9 and miR-21 targets in PCa using the CRISPR-Cas9 system. Single guide RNAs (sgRNAs) of MMP9 and miR-21 sequences were inserted into a PX-330 plasmid, and transfected in DU145 and PC-3 PCa cell lines. MMP9 and RECK expression was assessed by qPCR, WB, and IF. The miR-21 targets, integrins, BAX and mTOR, were evaluated by qPCR. Flow cytometry was performed with Annexin5, 7-AAD and Ki67 markers. Invasion assays were performed with Matrigel. The miR-21 CRISPR-Cas9-edited cells upregulated RECK, MARCKS, BTG2, and PDCD4. CDH1, ITGB3 and ITGB1 were increased in MMP9 and miR-21 CRISPR-Cas9-edited cells. Increased BAX and decreased mTOR were observed in MMP9 and miR-21 CRISPR-Cas9-edited cells. Reduced cell proliferation, increased apoptosis and low invasion in MMP9 and miR-21 edited cells was observed, compared to Scramble. CRISPR-Cas9-edited cells of miR-21 and MMP9 attenuate cell proliferation, invasion and stimulate apoptosis, impeding PCa evolution.

4 December 2017 in BMC Urology
Verified
Journal Article
Open access
PDF file
RORita de Cássia Oliveira
Rita de Cássia Oliveira
RIRenato Fidelis Ivanovic
Renato Fidelis Ivanovic
KLKatia Ramos Moreira Leite
Katia Ramos Moreira Leite
NVNayara Viana
Nayara Viana
Ruan PimentaRuan Pimenta
Ruan Pimenta
SRSabrina Thalita Reis
Sabrina Thalita Reis
Clear cell renal cell carcinoma (ccRCC) is the third most common urological cancer in adults. Our aim is to evaluate genes and miRNAs expression profiles involved with angiogenesis and tumor characteristics in ccRCC. The expression levels of miRNAs miR-99a, 99b, 100; 199a; 106a; 106b; 29a; 29b; 29c; 126; 200a, 200b and their respective target genes: mTOR, HIF1-α, VHL, PDGF, VEGF, VEGFR1 and VEGFR2 were analyzed using qRT-PCR in tumor tissue samples from 56 patients with ccRCC. Five samples of benign renal tissue were utilized as control. The expression levels of miRNAs and genes were related to tumor size, Fuhrman nuclear grade and microvascular invasion. miR99a was overexpressed in most samples and its target gene mTOR was underexpressed, this also occurs for miRNAs 106a, 106b, and their target gene VHL. An increase in miR-200b was correlated with high-risk tumors (p = 0.01) while miR-126 overexpression was associated with Fuhrman’s low grade (p = 0.03). Our results show that in ccRCC there are changes in miRNAs expression affecting gene expression that could be important in determining the aggressiveness of this lethal neoplasia.

1 December 2015 in International braz j urol
Verified
Journal Article
Open access
PDF file
SRSabrina Thalita dos Reis
Sabrina Thalita dos Reis
NVNayara Viana
Nayara Viana
AIAlexandre Iscaife
Alexandre Iscaife
JJJosé Pontes Junior
José Pontes Junior
NDNelson Dip
Nelson Dip
KLKatia Ramos Moreira Leite
Katia Ramos Moreira Leite
Key words: Prostatic Neoplasms; Matrix Metalloproteinases; Prognosis; Diagnosis; Gene Expression

1 December 2021
Verified
Journal Article
Open access
RMRodolfo Pacheco de Moraes
Rodolfo Pacheco de Moraes
Ruan PimentaRuan Pimenta
Ruan Pimenta
FMFernando Noboru Cabral Mori
Fernando Noboru Cabral Mori
GSGabriel Arantes dos Santos
Gabriel Arantes dos Santos
NVNayara Viana
Nayara Viana
SRSabrina T. Reis
Sabrina T. Reis
Prostate cancer is the most frequent malignancy affecting men worldwide. Due to the low sensitivity and specificity of the prostate-specific antigen test and the digital rectal exam as screening modalities, several alternatives are being studied. This study aimed to evaluate the application of MMP-9 and its regulators (TIMP-1, RECK, and miR-338-3p) as diagnostic and prognostic indicators of prostate cancer. A total of 134 randomly selected patients under investigation for prostate cancer submitted to a transrectal ultrasound-guided prostate biopsy were enrolled in the study; of these, 61 were positive for the disease (cases), and 73 were negative (control group). The tissue samples were further analyzed by gene and miR-338-3p expression analysis using qRT-PCR (one randomly selected fragment of each patient). Approximately 58% of the patients with prostate cancer presented MMP9 upregulation, while 73%, 65%, and 69% downregulated IMP-1, RECK, and miR-338-3p, respectively. MiR-338-3p was expressed at lower levels in patients with PSA concentrations exceeding 20 ng/mL (p=0.045) and abnormal DRE (p=0.006), while the RECK was more expressed in patients with abnormal DRE (p=0.01). We found that most patients with prostate cancer overexpressed MMP-9; on the other hand, most of them underexpressed TIMP-1, RECK, and miR-338-3p. MiR-338-3p presented as a possible predictor of poor prognosis. Further studies are warranted to evaluate these biomarkers as prognosis factors better.